Obiltoxaximab: Difference between revisions
(Created page with "==Administration== *Type: Monoclonal Antibody *Dosage Forms: IV *Routes of Administration: IV *Common Trade Names: Anthim *Info: Distributed directly to CDC ==Adult Dosing==...") |
No edit summary |
||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Inhalation anthrax treatment=== | |||
*<40 kg | |||
**24 mg/kg IV x1 | |||
***Premed with [[diphenhydramine]] | |||
*>40 kg | |||
**16 mg/kg IV x1 | |||
***Premed with [[diphenhydramine]] | |||
===Inhalation anthrax prophylaxis, post-exposure=== | |||
*<40 kg | |||
**24 mg/kg IV x1 | |||
***Do not use as 1st line agent | |||
***Premed with [[diphenhydramine]] | |||
*>40 kg | |||
**16 mg/kg IV x1 | |||
***Do not use as 1st line agent | |||
***Premed with [[diphenhydramine]] | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Inhalation anthrax treatment=== | |||
*<15 kg | |||
**32 mg/kg IV x1 | |||
***Premed with [[diphenhydramine]] | |||
*16-40 kg | |||
**24 mg/kg IV x1 | |||
***Premed with [[diphenhydramine]] | |||
*>40 kg | |||
**16 mg/kg IV x1 | |||
***Premed with [[diphenhydramine]] | |||
===Inhalation anthrax prophylaxis, post-exposure=== | |||
*<15 kg | |||
**32 mg/kg IV x1 | |||
***Do not use as 1st line agent | |||
***Premed with [[diphenhydramine]] | |||
*16-40 kg | |||
**24 mg/kg IV x1 | |||
***Do not use as 1st line agent | |||
***Premed with [[diphenhydramine]] | |||
*>40 kg | |||
**16 mg/kg IV x1 | |||
***Do not use as 1st line agent | |||
***Premed with [[diphenhydramine]] | |||
==Special Populations== | ==Special Populations== | ||
Revision as of 13:42, 14 February 2017
Administration
- Type: Monoclonal Antibody
- Dosage Forms: IV
- Routes of Administration: IV
- Common Trade Names: Anthim
- Info: Distributed directly to CDC
Adult Dosing
Inhalation anthrax treatment
- <40 kg
- 24 mg/kg IV x1
- Premed with diphenhydramine
- 24 mg/kg IV x1
- >40 kg
- 16 mg/kg IV x1
- Premed with diphenhydramine
- 16 mg/kg IV x1
Inhalation anthrax prophylaxis, post-exposure
- <40 kg
- 24 mg/kg IV x1
- Do not use as 1st line agent
- Premed with diphenhydramine
- 24 mg/kg IV x1
- >40 kg
- 16 mg/kg IV x1
- Do not use as 1st line agent
- Premed with diphenhydramine
- 16 mg/kg IV x1
Pediatric Dosing
Inhalation anthrax treatment
- <15 kg
- 32 mg/kg IV x1
- Premed with diphenhydramine
- 32 mg/kg IV x1
- 16-40 kg
- 24 mg/kg IV x1
- Premed with diphenhydramine
- 24 mg/kg IV x1
- >40 kg
- 16 mg/kg IV x1
- Premed with diphenhydramine
- 16 mg/kg IV x1
Inhalation anthrax prophylaxis, post-exposure
- <15 kg
- 32 mg/kg IV x1
- Do not use as 1st line agent
- Premed with diphenhydramine
- 32 mg/kg IV x1
- 16-40 kg
- 24 mg/kg IV x1
- Do not use as 1st line agent
- Premed with diphenhydramine
- 24 mg/kg IV x1
- >40 kg
- 16 mg/kg IV x1
- Do not use as 1st line agent
- Premed with diphenhydramine
- 16 mg/kg IV x1
Special Populations
- Pregnancy Rating: C; Benefits outweigh risks during pregnancy.
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypersensitivity reaction
- Anaphylaxis
Common
- Hypersensitivity reaction
- Headache
- URI
- Pruritus
- Cough
- Injection site reaction
- Nasal congestion
- Urticaria
- Extremity pain
Pharmacology
- Half-life: 15-23 Days
- Metabolism: Other; CYP450: unknown
- Excretion: Other
Mechanism of Action
- A monoclonal antibody that binds to anthrax toxin to prevent lethal and edema factors' intracellular entry and neutralizes toxic effects.